 |
|
|
Links to Other Materials
Menopausal Hormone Therapy Information from NIH
The links on this page point to information resources, including the most current from the National Institutes of Health (NIH), on both long-term and short-term hormone use, and other concerns related to women's health during and after menopause.
NIH Asks Participants in Women's Health Initiative Estrogen-Alone Study to Stop Study Pills, Begin Follow-up Phase
A March 2, 2004 announcement from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health concerning the decision to have WHI participants in the estrogen-alone arm of the study stop taking study medications and enter the follow-up phase.
Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women
The Food and Drug Administration provides updated product information for estrogen- and progestin-containing drug products used for treating postmenopausal symptoms.
NHLBI Stops Trial of Estrogen Plus Progestin Due to Increased Breast Cancer Risk, Lack of Overall Benefit
A July 9, 2002, announcement from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health concerning the decision to stop early a major clinical trial of the risks and benefits of combined estrogen and protestin in healthy menopausal women due to an increased risk of invasive breast cancer.
The Women's Health Initiative (WHI)
A page of information about the WHI maintained by the National Heart, Lung, and Blood Institute (NHLBI), the initiative's lead sponsor.
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women
Principal results from the Women's Health Initiative randomized controlled trial, as published in the July 17, 2002, issue of the Journal of the American Medical Association (JAMA).
U.S. Preventive Services Task Force & HRT
To determine the current status of benefits and harms of hormone replacement therapy (HRT) use, systematic searches of the literature on HRT were conducted for the U.S. Preventive Services Task Force.
< Previous Section | Next Section > |
|
|
